We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, announced that it has entered into an exclusive license and collaboration agreement with Shanghai-based ...